Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 2
Submit an article Journal homepage
972
Views
15
CrossRef citations to date
0
Altmetric
Letter to the Editor

Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts

Ali TabarrokiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Yogen SaunthararajahDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Valeria VisconteDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Tracy CinalliLeukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Kristin ColalucaLeukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Heesun J. RogersDepartment of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA
,
Mikkael A. SekeresDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Hien K. DuongLeukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Brady L. SteinDivison of Hematology and Oncology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, USACorrespondence[email protected]
&
Ramon V. TiuDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USACorrespondence[email protected]
 show all
Pages 497-499 | Received 16 Jan 2014, Accepted 16 Apr 2014, Published online: 27 May 2014

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Pasquale Niscola, Nélida Inés Noguera, Gianfranco Catalano, Luca Cupelli, Stefano Fratoni, Marco Giovannini, Carla Mazzone, Benedetta Neri, Laura Scaramucci, Malgorzata Monika Trawinska, Paolo de Fabritiis & Elisabetta Abruzzese. (2019) Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy. Acta Oncologica 58:6, pages 888-890.
Read now
Lise-Marie Mollard, Aurélie Chauveau, Françoise Boyer-Perrard, Nathalie Douet-Guilbert, Roch Houot, Isabelle Quintin-Roué, Marie-Anne Couturier, Anaig Dagorne, Mohamed Malou, Ronan Le Calloch, Odile Luycx, Sylvain Thepot, Mathilde Hunault, Gaelle Guillerm, Christian Berthou, Valérie Ugo, Éric Lippert & Jean-Christophe Ianotto. (2018) Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase. Leukemia & Lymphoma 59:12, pages 2812-2820.
Read now
Kiran Naqvi, Naval Daver, Naveen Pemmaraju, Prithviraj Bose, Guillermo Garcia-Manero, Jorge Cortes, Hagop M. Kantarjian & Srdan Verstovsek. (2017) Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leukemia & Lymphoma 58:4, pages 866-871.
Read now
Brady L. Stein, Francisco Cervantes, Francis Giles, Claire N. Harrison & Srdan Verstovsek. (2015) Novel therapies for myelofibrosis. Leukemia & Lymphoma 56:10, pages 2768-2778.
Read now
Naval Daver & Srdan Verstovsek. (2015) Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leukemia & Lymphoma 56:2, pages 279-280.
Read now

Articles from other publishers (10)

Vamsidhar Velcheti, David Schrump & Yogen Saunthararajah. 2021. Lung Cancer. Lung Cancer 237 259 .
Lanzhu Yue, Vasundhara Sharma, Nathan P. HorvatAfua A. AkuffoMatthew S. BeattyCem Murdun, Christelle ColinJulia M. R. Billington, William E. GoodheartEva Sahakian, Ling ZhangJohn J. Powers, Narmin E. Amin, Que T. Lambert-ShowersLancia N. DarvilleJavier Pinilla-IbarzGary W. Reuther, Kenneth L. Wright, Chiara ContiJennifer Y. LeeXiaozhang ZhengPui Yee NgMatthew W. Martin, C. Gary MarshallJohn M. Koomen, Ross L. LevineAmit Verma, H. Leighton Grimes, Eduardo M. Sotomayor, Zonghong ShaoPearlie K. Epling-Burnette. (2020) HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood 135:3, pages 191-207.
Crossref
Panagiotis T. Diamantopoulos, Nefeli Giannakopoulou, Sevastianos Hatzidavid & Nora-Athina Viniou. (2019) Post-Myelofibrosis Acute Myeloid Leukemia Effectively Treated with a Combination of Ruxolitinib and 5-Azacytidine. Oncology Research and Treatment 42:10, pages 532-535.
Crossref
Animesh Pardanani & Ayalew Tefferi. (2018) How I treat myelofibrosis after failure of JAK inhibitors. Blood 132:5, pages 492-500.
Crossref
Vamsidhar VelchetiDavid SchrumpYogen Saunthararajah. (2018) Ultimate Precision: Targeting Cancer but Not Normal Self-replication. American Society of Clinical Oncology Educational Book:38, pages 950-963.
Crossref
Michael Leung, Kaitlin Highsmith & Amber Rexwinkle. (2016) Pharmacologic management of myelofibrosis. Journal of Oncology Pharmacy Practice 23:8, pages 591-601.
Crossref
Kristen Pettit & Olatoyosi Odenike. (2017) Novel Therapies for Myelofibrosis. Current Hematologic Malignancy Reports 12:6, pages 611-624.
Crossref
Vamsidhar VelchetiTomas RadivoyevitchYogen Saunthararajah. (2017) Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer. American Society of Clinical Oncology Educational Book:37, pages 812-824.
Crossref
Thamer Sliwa, Christine Beham-Schmid, Sonja Burgstaller, Veronika Buxhofer-Ausch, Günther Gastl, Klaus Geissler, Maria Krauth, Peter Krippl, Alois Lang, Andreas Petzer, Stefan Wöhrer, Albert Wölfler & Heinz Gisslinger. (2016) Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. Wiener klinische Wochenschrift 129:9-10, pages 293-302.
Crossref
Srdan VerstovsekSrdan Verstovsek & Kate J Newberry. 2015. Novel Insights into Myelofibrosis Pathophysiology and Treatment. Novel Insights into Myelofibrosis Pathophysiology and Treatment 104 122 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.